Equasens: Q1 2024 revenue

Villers-lès-Nancy, 7 May 2024 - 6:00 p.m. (CET)PRESS RELEASE Q1 2024 revenue: €53.3 million Contributions from new acquisitions offset the base effect from the Ségur digital healthcare investment programme.The Divisions that sell equipment are heavily impacted by the economic context.2024 outlook: after a phase of significant investment, the Group is targeting a return to growth beginning in H2. Q1revenue (€m)2023 reported basis2024 reported basis...

Villers Les Nancy, 07/05/2024 (informazione.it - comunicati stampa - information technology)

Villers-lès-Nancy, 7 May 2024 - 6:00 p.m. (CET)

PRESS RELEASE

Q1 2024 revenue: €53.3 million

Equasens Group reported revenue in the first quarter of €53.3m, down 5.2% from Q1 2023, with a marginal improvement on Q4 2023 (-5.5%).

Operating highlights:

The acquisitions completed in 2023 and early 2024 are already contributing to Q1 sales (€2.0m), confirming their fit with the Group's strategy.
Acquisitions within the PHARMAGEST Division:

PRATILOG, a provider of software solutions for private practice doctors and allied health professionals working in hospitals, has been added to the MEDICAL SOLUTIONS Division's offering.

The unfavourable economic climate is having a more significant impact on the Group's hardware divisions, particularly PHARMAGEST and E-CONNECT. The adverse effect of drug shortages, increased sales of expensive drugs with capped mark-ups and high interest rates on pharmacy margins have contributed to a significant slowdown in investment. This trend, combined with the increase in pharmacy closures, is directly reflected in the Group's financial statements.

At the same time, the growth of all businesses, with the exception of equipment sales, highlights the relevance of the Group's strategy in adapting to new market trends by increasing its SaaS offering.

This Division, with a significant European footprint, accounts for 75% of Equasens Group's revenue.

This Division accounted for 15% of Equasens Group's total revenue.

This Division accounted for 5% of Equasens Group's total revenue.

This Division accounted for 4% of Equasens Group's total revenue.
In 2023, the Ségur programme helped consolidate the Division's customer base through the widespread use of the MédiStory 4 version. In Q1 2024, revenue returned to a normal level. It should be noted that recurring revenue now accounts for 50% of total revenue.

This Division accounted for 1% of Equasens Group's total revenue.

2024 outlook

Financial calendar:

About Group Equasens

With more than 1,300 employees, Equasens Group is today a key player in the European healthcare sector, providing software solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, hospital-at-home programmes, retirement homes, health centres) in both primary and secondary care sectors.

With operations in in France, Germany, Great Britain, Belgium, Ireland, Italy, and Luxembourg, Equasens Group today brings together healthcare professionals within a unique ecosystem in France and Europe benefiting people by making available the very best of technology.

Listed on Euronext Paris™ - Compartment B

Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC SMALL and CAC All-Tradable
Included in the Euronext Tech Leaders segment and the European Rising Tech label

Eligible for the Deferred Settlement Service (“Service à Réglement Différé” - SRD) and equity savings accounts invested in small and mid caps (PEA-PME).
ISIN: FR 0012882389 – Ticker Code: EQS

Get all the news about the Equasens Group www.equasens.com and on LinkedIn

CONTACTS

Analyst and Investor Relations:
Chief Administrative and Financial Officer: Frédérique Schmidt
Tel: +33 (0)3 83 15 90 67 - frederique.schmidt@equasens.com

Media Relations:
FIN'EXTENSO - Isabelle Aprile

Tel.: +33 (0)6 17 38 61 78 - i.aprile@finextenso.fr

Attachment